📰 Samir Kumar Patel News
Samir Kumar Patel News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Samir Kumar Patel. Real-time updates on events, politics, business and more.
June 4, 2023
Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Rating) has received a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price target […]
May 26, 2023
Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Rating) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totalling 568,400 shares, an increase of 102.8% from the April 30th total of 280,300 shares. Approximately 1.1% of the company’s shares are short sold. Based on an average […]
May 21, 2023
StockNews.com upgraded shares of Clearside Biomedical (NASDAQ:CLSD – Get Rating) from a sell rating to a hold rating in a research report released on Wednesday. Several other research firms have also recently weighed in on CLSD. 500.com reissued a reiterates rating on shares of Clearside Biomedical in a research note on Friday, April 28th. HC […]
May 18, 2023
StockNews.com upgraded shares of Clearside Biomedical (NASDAQ:CLSD – Get Rating) from a sell rating to a hold rating in a research note released on Wednesday. Other research analysts also recently issued reports about the company. 500.com reiterated a reiterates rating on shares of Clearside Biomedical in a research report on Friday, April 28th. JMP Securities […]
May 13, 2023
StockNews.com cut shares of Clearside Biomedical (NASDAQ:CLSD – Get Rating) from a hold rating to a sell rating in a research report released on Tuesday morning. CLSD has been the subject of several other research reports. Needham & Company LLC restated a buy rating and set a $4.00 price target on shares of Clearside Biomedical […]
May 12, 2023
StockNews.com lowered shares of Clearside Biomedical (NASDAQ:CLSD – Get Rating) from a hold rating to a sell rating in a research note released on Tuesday morning. Several other research firms have also issued reports on CLSD. JMP Securities lowered their price target on Clearside Biomedical from $7.00 to $6.00 and set a market outperform rating […]
May 8, 2023
Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Rating) has received a consensus rating of “Moderate Buy” from the seven ratings firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12 month target price among […]
May 2, 2023
500.com reiterated their reiterates rating on shares of Clearside Biomedical (NASDAQ:CLSD – Get Rating) in a research note published on Friday morning, Benzinga reports. A number of other research firms have also recently weighed in on CLSD. HC Wainwright restated a buy rating and issued a $6.00 price target on shares of Clearside Biomedical in […]
May 1, 2023
Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Rating) was the recipient of a large drop in short interest in April. As of April 15th, there was short interest totalling 269,600 shares, a drop of 19.6% from the March 31st total of 335,500 shares. Currently, 0.5% of the shares of the stock are sold short. Based on […]
April 30, 2023
Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Rating) saw a significant decline in short interest in April. As of April 15th, there was short interest totalling 269,600 shares, a decline of 19.6% from the March 31st total of 335,500 shares. Currently, 0.5% of the shares of the company are sold short. Based on an average daily […]